Logotype for Lantern Pharma Inc

Lantern Pharma (LTRN) Proxy filing summary

Event summary combining transcript, slides, and related documents.

Logotype for Lantern Pharma Inc

Proxy filing summary

19 Oct, 2026

Executive summary

  • Virtual annual meeting scheduled for Dec. 1, 2026; holders of record on Oct. 5, 2026 may vote, with 14,935,576 common shares outstanding and one vote per share.

  • Board recommends FOR all seven proposals, including six director nominees, capital and equity-plan amendments, warrant-share issuance, auditor ratification, say-on-pay, and annual say-on-pay votes.

Voting matters and shareholder proposals

  • Proposal 1 seeks election of Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Lee T. Schalop, and David S. Silberstein for one-year terms; plurality vote elects the six nominees.

  • Proposal 2 would double authorized common shares from 25 million to 50 million; only 281,597 shares were unissued and unreserved as of Oct. 5, 2026.

  • Proposal 3 seeks 250,000 additional Equity Incentive Plan shares, bringing the plan reserve to 2,114,680; 425,633 shares would be available for new awards if approved.

  • Proposal 4 seeks approval for up to 3,669,725 warrant shares at $1.09 each; full exercise could yield ~$4.0 million for working capital and general purposes while diluting existing holders.

  • Proposals 5–7 seek 2026 EisnerAmper ratification, advisory executive-pay approval, and a preferred say-on-pay frequency; the Board recommends FOR and one year, respectively.

Board of directors and corporate governance

  • Board has six members, five independent; Donald Jeff Keyser is chair and Panna Sharma is CEO and president, with no lead director.

  • In 2025, the Board met six times and acted five times by unanimous written consent; all directors attended at least 75% of Board and committee meetings.

  • Independent Audit, Compensation, and Nominating and Corporate Governance committees oversee their respective mandates; committee chairs are Keyser, Maccecchini, and Chandru.

  • Proxy access permits a holder or group of up to 10 with at least 3% ownership for three years to nominate up to the greater of two directors or 20% of the Board, subject to bylaw requirements.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Lantern Pharma